Genmab A/S (NASDAQ:GMAB) Receives Average Rating of “Hold” from Analysts

Shares of Genmab A/S (NASDAQ:GMAB) have earned an average recommendation of “Hold” from the thirteen ratings firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $45.20.

GMAB has been the subject of a number of recent research reports. BTIG Research lifted their target price on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, June 27th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Friday. Truist Financial dropped their price objective on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, September 9th. Morgan Stanley reaffirmed an “equal weight” rating and set a $31.00 price objective on shares of Genmab A/S in a research report on Wednesday, September 11th. Finally, Royal Bank of Canada raised Genmab A/S from a “sector perform” rating to an “outperform” rating in a report on Monday, July 15th.

Hedge Funds Weigh In On Genmab A/S

Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC increased its stake in shares of Genmab A/S by 360.5% during the first quarter. SG Americas Securities LLC now owns 29,500 shares of the company’s stock worth $882,000 after acquiring an additional 23,094 shares during the period. Harding Loevner LP increased its position in Genmab A/S by 2.7% during the 4th quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock worth $97,569,000 after purchasing an additional 85,665 shares during the period. Capital International Investors raised its stake in shares of Genmab A/S by 7.8% during the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after buying an additional 315,355 shares in the last quarter. Aigen Investment Management LP acquired a new stake in shares of Genmab A/S in the 4th quarter valued at approximately $1,143,000. Finally, Choreo LLC purchased a new stake in shares of Genmab A/S in the second quarter valued at approximately $776,000. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Price Performance

Shares of GMAB stock opened at $26.90 on Wednesday. Genmab A/S has a 1-year low of $24.53 and a 1-year high of $38.80. The firm has a market cap of $17.79 billion, a PE ratio of 22.42, a price-to-earnings-growth ratio of 0.81 and a beta of 0.99. The company has a 50-day moving average of $27.25 and a two-hundred day moving average of $28.06.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The firm had revenue of $779.50 million for the quarter, compared to analyst estimates of $734.60 million. Sell-side analysts anticipate that Genmab A/S will post 1.27 EPS for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.